NASDAQ:CDXC

ChromaDex (CDXC) Stock Forecast, Price & News

$1.43

0.00 (0.00%)

(As of 10:23 AM ET)

Compare

Today's Range: $1.42
▼
$1.47
50-Day Range: $1.31
▼
$1.68
52-Week Range: $1.15
▼
$2.37

Volume: 4,918 shs
Average Volume: 156,150 shs
Market Capitalization: $107.21 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $4.57

ChromaDex MarketRank™ Forecast

Analyst Rating: Hold
2.33 Rating Score
Upside/Downside: 219.3% Upside
$4.57 Price Target
Short Interest: Bearish
3.80% of Float Sold Short
Dividend Strength: N/A
Sustainability: -1.55
Upright™ Environmental Score
News Sentiment: 0.83
Based on 4 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.13) to ($0.06) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.14 out of 5 stars

Medical Sector

497th out of 1,009 stocks

Medicinals & Botanicals Industry

4th out of 12 stocks

3.2

Analyst's Opinion

Consensus Rating
ChromaDex has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $4.57, ChromaDex has a forecasted upside of 219.3% from its current price of $1.43.
Amount of Analyst Coverage
ChromaDex has only been the subject of 1 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
3.80% of the float of ChromaDex has been sold short.
Short Interest Ratio / Days to Cover
ChromaDex has a short interest ratio ("days to cover") of 11.7, which indicates bearish sentiment.
Change versus previous month
Short interest in ChromaDex has recently decreased by 3.14%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
ChromaDex does not currently pay a dividend.
Dividend Growth
ChromaDex does not have a long track record of dividend growth.

4.3

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
ChromaDex has received a 63.13% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Preclinical research services for physical health", "Clinical research services for physical health", and "Dietary supplements" products. See details.
Environmental Sustainability
The Environmental Impact score for ChromaDex is -1.55.

2.7

News and Social Media Coverage

News Sentiment
ChromaDex has a news sentiment score of 0.83. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for ChromaDex this week, compared to 2 articles on an average week.
Search Interest
6 people have searched for CDXC on MarketBeat in the last 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, ChromaDex insiders have not sold or bought any company stock.
Percentage Held by Insiders
11.80% of the stock of ChromaDex is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
42.81% of the stock of ChromaDex is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for ChromaDex are expected to grow in the coming year, from ($0.13) to ($0.06) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of ChromaDex is -9.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of ChromaDex is -9.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
ChromaDex has a P/B Ratio of 3.67. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About ChromaDex (NASDAQ:CDXC) Stock

Chromadex Corp. is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company's patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services. The Consumer Products segment provides finished dietary supplement products that contain the firm's proprietary ingredients directly to consumers as well as to distributors. The Ingredients segment supplies ingredients as raw materials to the manufacturers of consumer products. The Analytical Reference Standards and Services segment includes supply of phytochemical reference standards and other research and development services. The company was founded by Mark S. Germain and Frank L. Jaksch, Jr. in 1999 and is headquartered in Los Angeles, CA.

Receive CDXC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ChromaDex and its competitors with MarketBeat's FREE daily newsletter.

CDXC Stock News Headlines

May 30, 2023 | finance.yahoo.com

ChromaDex to Participate in the LD Micro Invitational XIII

May 26, 2023 | americanbankingnews.com

ChromaDex (NASDAQ:CDXC) Stock Rating Upgraded by StockNews.com

May 30, 2023 | Edge On The Street (Ad)

New "Mined in America" Lithium Opportunities?

The average electric vehicle needs 138 pounds of lithium carbonate for its battery components. But China currently controls the entire lithium supply chain.

May 17, 2023 | americanbankingnews.com

ChromaDex (NASDAQ:CDXC) Rating Increased to Strong-Buy at StockNews.com

May 14, 2023 | americanbankingnews.com

LADENBURG THALM/SH SH Trims ChromaDex (NASDAQ:CDXC) Target Price to $6.60

May 11, 2023 | msn.com

Recap: ChromaDex Q1 Earnings

May 11, 2023 | finance.yahoo.com

ChromaDex to Present at the Lytham Partners Spring 2023 Investor Conference

May 10, 2023 | finance.yahoo.com

ChromaDex Corporation Reports First Quarter 2023 Financial Results

May 30, 2023 | Edge On The Street (Ad)

Is Graphite the New Lithium?

Did you know that graphite (NOT lithium) is the largest component of lithium batteries used for EV's? Unfortunately, there are no graphite-producing mines in North America today. This leaves the U.S. at the mercy of China for our vital graphite supply.

May 8, 2023 | americanbankingnews.com

ChromaDex (CDXC) Scheduled to Post Earnings on Wednesday

May 2, 2023 | finance.yahoo.com

ChromaDex to Report First Quarter 2023 Financial Results on Wednesday, May 10, 2023

April 29, 2023 | ca.finance.yahoo.com

ChromaDex Corporation (CDXC) Interactive Stock Chart - Yahoo Finance

April 12, 2023 | finance.yahoo.com

Individual investors account for 44% of ChromaDex Corporation's (NASDAQ:CDXC) ownership, while insiders account for 26%

April 3, 2023 | americanbankingnews.com

ChromaDex Co. (NASDAQ:CDXC) Short Interest Down 6.7% in March

March 27, 2023 | finance.yahoo.com

Bullish ChromaDex Corporation (NASDAQ:CDXC) insiders filled their treasuries with US$1.6m worth of stock over last year

March 10, 2023 | finance.yahoo.com

ChromaDex Full Year 2022 Earnings: EPS Misses Expectations

March 10, 2023 | finance.yahoo.com

ChromaDex Corporation (NASDAQ:CDXC) Q4 2022 Earnings Call Transcript

March 8, 2023 | finance.yahoo.com

ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2022 Results

March 6, 2023 | finance.yahoo.com

ChromaDex to Participate at the 35th Annual ROTH Capital Partners Conference on March 13, 2023

February 27, 2023 | finance.yahoo.com

ChromaDex to Report Fourth Quarter and Fiscal Year 2022 Financial Results on Wednesday, March 8, 2023

February 22, 2023 | finance.yahoo.com

ChromaDex Announces Issuance of New U.S. Patent on Dihydronicotinamide Riboside (NRH) and Dihydronicotinic Acid Riboside (NARH), Further Solidifying ChromaDex as the Leader in the Nicotinamide Adenine Dinucleotide (NAD+) Precursor Space

February 21, 2023 | finance.yahoo.com

A Letter from the ChromaDex Chief Executive Officer

February 20, 2023 | finance.yahoo.com

ChromaDex Corporation (CDXC) Stock Historical Prices & Data - Yahoo Finance

January 31, 2023 | finance.yahoo.com

ChromaDex Shares Promising Findings from a Clinical Study Showcasing Combined Metabolic Activators (CMAs), Featuring Nicotinamide Riboside (NR), Improved Cognitive Functions in Alzheimer's Disease (AD) Patients

January 17, 2023 | finance.yahoo.com

ChromaDex Shares Promising Findings from First-Of-Its Kind Clinical Study to Demonstrate Oral Nicotinamide Riboside (NR) Supplementation Increases Muscle Mitochondrial Biogenesis

January 15, 2023 | finance.yahoo.com

Strong week for ChromaDex (NASDAQ:CDXC) shareholders doesn't alleviate pain of five-year loss

January 5, 2023 | finance.yahoo.com

ChromaDex Named Brianna Gerber Chief Financial Officer

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive CDXC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ChromaDex and its competitors with MarketBeat's FREE daily newsletter.

CDXC Company Calendar

Last Earnings: 3/08/2023
Today: 5/30/2023
Next Earnings (Estimated): 8/09/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Medicinals & botanicals
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:CDXC
CUSIP: N/A
CIK: 1386570
Web: www.chromadex.com
Phone: (310) 388-6706
Fax: 949-419-0294
Employees: 115
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $4.57
High Stock Price Forecast: $6.60
Low Stock Price Forecast: $2.10
Forecasted Upside/Downside: +219.3%
Consensus Rating: Hold
Rating Score (0-4): 2.33
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.15)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-16,540,000.00
Net Margins: -13.84%
Pretax Margin: -13.84%
Return on Equity: -51.99%
Return on Assets: -25.59%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 2.53
Quick Ratio: 1.88

Sales & Book Value

Annual Sales: $72.05 million
Price / Sales: 1.49
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.39 per share
Price / Book: 3.67

Miscellaneous

Outstanding Shares: 74,970,000
Free Float: 66,120,000
Market Cap: $107.21 million
Optionable: Optionable
Beta: 1.79

Key Executives

Robert N. Fried
Chief Executive Officer & Director

Brianna Gerber
Chief Financial Officer

Fadi Karam
Chief Marketing Officer

Trent Crane
Regional Vice President-Sales

Heather Van Blarcom
Secretary & Senior Vice President-Legal

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

CDXC Stock - Frequently Asked Questions

Should I buy or sell ChromaDex stock right now?: 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for ChromaDex in the last twelve months. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" CDXC shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CDXC, but not buy additional shares or sell existing shares.
View CDXC analyst ratings or view top-rated stocks.
What is ChromaDex's stock price forecast for 2023?: 3 brokerages have issued 12 month price objectives for ChromaDex's shares. Their CDXC share price forecasts range from $2.10 to $6.60. On average, they anticipate the company's stock price to reach $4.57 in the next year. This suggests a possible upside of 219.3% from the stock's current price.
View analysts price targets for CDXC or view top-rated stocks among Wall Street analysts.
How have CDXC shares performed in 2023?: ChromaDex's stock was trading at $1.68 at the beginning of the year. Since then, CDXC stock has decreased by 14.9% and is now trading at $1.43.
View the best growth stocks for 2023 here.
When is ChromaDex's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 9th 2023.
View our CDXC earnings forecast.
How were ChromaDex's earnings last quarter?: ChromaDex Co. (NASDAQ:CDXC) announced its quarterly earnings data on Wednesday, March, 8th. The company reported ($0.02) EPS for the quarter, topping analysts' consensus estimates of ($0.03) by $0.01. The business had revenue of $21 million for the quarter, compared to analysts' expectations of $21.08 million. ChromaDex had a negative net margin of 13.84% and a negative trailing twelve-month return on equity of 51.99%. During the same quarter in the previous year, the company posted ($0.08) EPS.
What guidance has ChromaDex issued on next quarter's earnings?: ChromaDex issued an update on its FY 2023 earnings guidance on Friday, May, 12th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $81.06M-, compared to the consensus revenue estimate of $82.65 million.
What is Robert Fried's approval rating as ChromaDex's CEO?: 13 employees have rated ChromaDex Chief Executive Officer Robert Fried on Glassdoor.com. Robert Fried has an approval rating of 38% among the company's employees. This puts Robert Fried in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. 46.0% of employees surveyed would recommend working at ChromaDex to a friend.

What other stocks do shareholders of ChromaDex own?: Based on aggregate information from My MarketBeat watchlists, some companies that other ChromaDex investors own include Sorrento Therapeutics (SRNE), Heron Therapeutics (HRTX), ADMA Biologics (ADMA), Athersys (ATHX), Bionano Genomics (BNGO), Matinas BioPharma (MTNB), Tilray (TLRY), Dynavax Technologies (DVAX), Glu Mobile (GLUU) and Great Panther Mining (GPL).
What is ChromaDex's stock symbol?: ChromaDex trades on the NASDAQ under the ticker symbol "CDXC."
Who are ChromaDex's major shareholders?: ChromaDex's stock is owned by a variety of retail and institutional investors. Top institutional investors include Tieton Capital Management LLC (3.41%), BlackRock Inc. (1.20%), Renaissance Technologies LLC (0.57%), GMT Capital Corp (0.40%), Cambridge Investment Research Advisors Inc. (0.26%) and State Street Corp (0.25%). Insiders that own company stock include Frank L Jaksch Jr, Hoi Shuen Solina Holly Chau, Kevin M Farr, Robert N Fried and Stephen A Block.
View institutional ownership trends.
How do I buy shares of ChromaDex?: Shares of CDXC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is ChromaDex's stock price today?: One share of CDXC stock can currently be purchased for approximately $1.43.
How much money does ChromaDex make?: ChromaDex (NASDAQ:CDXC) has a market capitalization of $107.21 million and generates $72.05 million in revenue each year. The company earns $-16,540,000.00 in net income (profit) each year or ($0.15) on an earnings per share basis.
How many employees does ChromaDex have?: The company employs 115 workers across the globe.
How can I contact ChromaDex?: ChromaDex's mailing address is 10900 Wilshire Blvd. Suite 650, Los Angeles CA, 90024. The official website for the company is www.chromadex.com. The company can be reached via phone at (310) 388-6706, via email at investorrelations@chromadex.com, or via fax at 949-419-0294.

This page (NASDAQ:CDXC) was last updated on 5/30/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial